Intravenous Immunoglobulin (IVIg) Market Outlook: Innovation, Access & Commercial Strategy (2024–2032) The IVIg market, comprising life-saving plasma‑derived immunoglobulin therapies used in autoimmune, neurologic, and immunodeficiency conditions, continues its steady growth. From an estimated USD 11.4 billion in 2023, the market is projected to reach approximately USD 12.0 billion in 2024, with forecasts aiming for USD 17.5 billion by 2032, reflecting a solid compound annual growth rate (CAGR) of ~5.5%. Growth is driven by expanding therapeutic indications, growing healthcare infrastructure, and improvements in plasma collection and manufacturing. https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137